Secondary analysis of four phase III trials and open-label extensions in axSpA (n=586) and PsA (n=1112): with bimekizumab, mean EQ VAS improved 20.2–21.3 (axSpA) and 17.1–17.3 points (PsA) by year 3; most had meaningful work-impairment improvement. Observed cases, no comparator.
Secondary analysisn = 1,698
Nikiphorou et al. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis